FLT3 Mutations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Multi-Center Analysis

FLT3 mutations are established high-risk drivers in acute myeloid leukemia (AML), but their role in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) remains poorly defined. We assembled 115 patients with FLT3-mutant MDS (n=63) or CMML (n=52) across six academic institutions and compared clinicogenomic features and outcomes with FLT3-wildtype controls using propensity score matching and multivariable modeling. FLT3-mutant MDS and CMML displayed a proliferative phenotype, with higher white blood cell counts, increased frequency of CMML-2, and significantly higher rates of AML transformation. FLT3-mutant MDS was enriched for signaling co-mutations, such as NRAS, PTPN11, and CBL, whereas FLT3-mutant CMML showed frequent co-mutation with ASXL1 and SRSF2. FLT3 mutations were independently associated with inferior survival in both entities. After matching, FLT3-mutant MDS had worse median overall survival (OS: 19.9 vs 44.2 months, p=0.046) and leukemia-free survival (LFS: 13.8 vs 37.1 months, p=0.023). In CMML, median OS was 30.4 vs 67.2 months (p=0.017) and LFS 17.2 vs 65.6 months (p=0.014). FLT3-TKD was associated with more favorable outcomes than FLT3-ITD. FLT3-targeted therapy was associated with longer survival in unadjusted comparisons (median OS 14.3 vs 45.9 months in MDS; 20.6 vs 35.0 months in CMML), although this association was attenuated and no longer statistically significant after accounting for immortal time bias introduced from variable treatment initiation timing (adjusted time-dependent HR 0.66, MDS; 0.64, CMML). These findings support early identification of FLT3-mutant MDS and CMML and highlight the need for prospective studies evaluating early therapeutic intervention in this high-risk molecular subset.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2026-11-20
DOI
https://doi.org/10.1182/bloodadvances.2026020859
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FLT3 Mutations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Multi-Center Analysis

Sandra Castaño‐Díez, Rami S. Komrokji, David Valcárcel, Jordi Esteve et al.
1 links
Blood Advances
Acute Myeloid Leukemia Research
article

FLT3 Mutations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Multi-Center Analysis

Sandra Castaño‐Díez, Rami S. Komrokji, David Valcárcel, Jordi Esteve, Xavier Calvo, Guillermo Montalban‐Bravo, Kelly Sharon Chien, David Andrew Sallman, Juan José Rodríguez‐Sevilla, Eric Padron, Clifford Michael Csizmar, Rashmi Kanagal‐Shamanna, Guillermo Garcia‐Manero, María Díez‐Campelo, Ruoxing Li, Mrinal M. Patnaik, Marina Díaz‐Beyá, Francesc Gessé Solé, Mónica Del Rey, Ziyi Li, Najla Al-Ali, Andrés Jerez, Maria Julia Montoro, Marina Cornejo Garcia, Abhishek A. Mangaonkar, Fatima Zahra Jelloul
article en

Abstract

FLT3 mutations are established high-risk drivers in acute myeloid leukemia (AML), but their role in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) remains poorly defined. We assembled 115 patients with FLT3-mutant MDS (n=63) or CMML (n=52) across six academic institutions and compared clinicogenomic features and outcomes with FLT3-wildtype controls using propensity score matching and multivariable modeling. FLT3-mutant MDS and CMML displayed a proliferative phenotype, with higher white blood cell counts, increased frequency of CMML-2, and significantly higher rates of AML transformation. FLT3-mutant MDS was enriched for signaling co-mutations, such as NRAS, PTPN11, and CBL, whereas FLT3-mutant CMML showed frequent co-mutation with ASXL1 and SRSF2. FLT3 mutations were independently associated with inferior survival in both entities. After matching, FLT3-mutant MDS had worse median overall survival (OS: 19.9 vs 44.2 months, p=0.046) and leukemia-free survival (LFS: 13.8 vs 37.1 months, p=0.023). In CMML, median OS was 30.4 vs 67.2 months (p=0.017) and LFS 17.2 vs 65.6 months (p=0.014). FLT3-TKD was associated with more favorable outcomes than FLT3-ITD. FLT3-targeted therapy was associated with longer survival in unadjusted comparisons (median OS 14.3 vs 45.9 months in MDS; 20.6 vs 35.0 months in CMML), although this association was attenuated and no longer statistically significant after accounting for immortal time bias introduced from variable treatment initiation timing (adjusted time-dependent HR 0.66, MDS; 0.64, CMML). These findings support early identification of FLT3-mutant MDS and CMML and highlight the need for prospective studies evaluating early therapeutic intervention in this high-risk molecular subset.

Blood Advances
Mayo Clinic (US), The University of Texas MD Anderson Cancer Center (US), Universidad de Salamanca (ES), Moffitt Cancer Center (US), Josep Carreras Leukaemia Research Institute (ES), Hospital Clínic de Barcelona (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Del Mar (ES), Instituto de Investigación Biomédica de Salamanca (ES), Centro de Investigación del Cáncer (ES), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Vall d'Hebron Institute of Oncology (ES), Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES)
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon